1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Integrase Inhibitors -Pipeline Insights, 2017


DelveInsight’s, “Integrase Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Integrase Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Integrase Inhibitors. DelveInsight’s Report also assesses the Integrase Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Integrase Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Integrase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Integrase Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Integrase Inhibitors -Pipeline Insights, 2017
Illustrative

- Integrase Inhibitors Overview
- Integrase Inhibitors Disease Associated
- Integrase Inhibitors Pipeline Therapeutics
- Integrase Inhibitors Therapeutics under Development by Companies
- Integrase Inhibitors Filed and Phase III Products
- Comparative Analysis
- Integrase Inhibitors Phase II Products
- Comparative Analysis
- Integrase Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Integrase Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Integrase Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Integrase Inhibitors - Discontinued Products
- Integrase Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Integrase Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer



List of Tables

- Number of Products under Development for Integrase Inhibitors by Therapy Area, 2017
- Number of Products under Development for Integrase Inhibitors, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Integrase Inhibitors Assessment by Monotherapy Products
- Integrase Inhibitors Assessment by Combination Products
- Integrase Inhibitors Assessment by Route of Administration
- Integrase Inhibitors Assessment by Stage and Route of Administration
- Integrase Inhibitors Assessment by Molecule Type
- Integrase Inhibitors Assessment by Stage and Molecule Type
- Integrase Inhibitors Therapeutics - Discontinued Products
- Integrase Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Integrase Inhibitors by Therapy Area, 2017
- Number of Products under Development for Integrase Inhibitors, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Integrase Inhibitors Assessment by Monotherapy Products
- Integrase Inhibitors Assessment by Combination Products
- Integrase Inhibitors Assessment by Route of Administration
- Integrase Inhibitors Assessment by Stage and Route of Administration
- Integrase Inhibitors Assessment by Molecule Type
- Integrase Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Programmed Death-1 & Programmed Death Ligand-1 Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Drug, by Mechanism of Action

Global Programmed Death-1 & Programmed Death Ligand-1 Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Drug, by Mechanism of Action

  • $ 6500
  • Industry report
  • January 2017
  • by P&S Market Research

Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors are the therapeutic candidates or drugs, popularly known as checkpoint inhibitors, used most commonly for the treatment of cance ...

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • October 2016
  • by Grand View Research

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one ...

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by Global Data

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview ...


Download Unlimited Documents from Trusted Public Sources

HIV AIDS Statistics and HIV Antiviral Market in China

  • February 2017
    11 pages
  • HIV AIDS  

    Infectious Dise...  

    HIV Antiviral  

  • China  

    United States  

View report >

HIV AIDS Statistics and HIV Antiviral Market in the US

  • January 2017
    4 pages
  • HIV AIDS  

    HIV Antiviral  

  • United States  

View report >

HIV Antiviral Market in Africa

  • January 2017
    27 pages
  • Antiviral  

    HIV Antiviral  

    HIV AIDS  

  • Africa  

    Asia  

View report >

Related Market Segments :

HIV Antiviral

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.